pmvpharma

PMV Pharma is developing first-in-class p53 reactivators for the treatment of cancer.

[pmvpharma @pmvpharma]

Celebrate #NationalDogDay with us!

At PMV Pharma we have a ‘bring your dog to work’ policy every day, which contributes to the fun, friendly, and social vibe in our office. Please enjoy these snapshots of our PMV pups!

[pmvpharma @pmvpharma]

PMV is thrilled to welcome Masha Poyurovsky, Ph.D., our new Vice President of Biology.

She has extensive experience in oncology research and development, including specific expertise on the #p53 cancer regulatory pathway.

Read more: https://t.co/pWiXB4ofxX

#precisiononcology

[pmvpharma @pmvpharma]

Today, PMV reported financial results for Q2 2023 and provided a corporate update, including an update about continued progress in the ongoing Phase 1/2 #PYNNACLE study of PC14586.

Read the press release here: https://t.co/kubJISLKqP

#p53 #precisiononcology

[pmvpharma @pmvpharma]

PMV Pharmaceuticals reported our first quarter 2023 financial results and corporate highlights today.

You can read the full press release here: https://t.co/d22jCbyyJu

[pmvpharma @pmvpharma]

Welcome to Arshad Haque, our new VP of Drug Safety & Pharmacovigilance. We're so excited to have you join us at PMV Pharma.

If you're interested in being part of our team, check out our open positions:

https://t.co/K1hUZoPPXY

#newhires #werehiring

[pmvpharma @pmvpharma]

Today, PMV reported financial results for 2022 and provided a corporate update.

Read the full release here: https://t.co/3o5j4rBpQQ

[pmvpharma @pmvpharma]

Today on #WorldCancerDay – and every other day of the year – PMV is committed to fundamentally disrupting the course of cancer by harnessing the power of #p53.

[pmvpharma @pmvpharma]

PMV will participate in a virtual fireside chat at the Evercore ISI HealthCONx Conference on Tuesday, November 29 at 3:05 p.m. ET.

You can find the details in our press release: https://t.co/xXQ9T8zc6R

[pmvpharma @pmvpharma]

Today, PMV reported our third quarter results.

Read the full press release here: https://t.co/TOrPEcZrrq

[pmvpharma @pmvpharma]

PMV is thrilled to announce that Carol Gallagher, Pharm.D., has joined our Board of Directors.

Dr. Gallagher brings 30+ years of biotech leadership and a stellar track record of drug development and commercialization.

Read the press release: https://t.co/awCfMR2cVN

[pmvpharma @pmvpharma]

Today, PMV Pharma announced our second-quarter 2022 financial results and business highlights.

Read the full press release here: https://t.co/c34XBaUfXa

[pmvpharma @pmvpharma]

We are thrilled to announce our collaboration with Merck to evaluate PC14586 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.

https://t.co/OfPXA2hyYH

#p53 #oncology

[pmvpharma @pmvpharma]

The team at @pmvpharma would like to wish everyone a happy and safe 4th of July!

#IndependenceDay #July4th

[pmvpharma @pmvpharma]

June is National Cancer Survivor Month.

Thanks to advances in cancer research, there are more than 16.9 million cancer survivors in the US.

Amazing progress has been made, but there is still work to be done:

https://t.co/UwqXnwSPvv

#ResearchSavesLives #CelebrateSurvivorship

[pmvpharma @pmvpharma]

@pmvpharma President & CEO David H. Mack, Ph.D. will participate in a fireside chat at the @GoldmanSachs
Global Healthcare Conference this afternoon from 1:20PM - 1:55PM PDT.

For more information, please visit https://t.co/jupv1ai3xt.

#CEO #firesidechat #GoldmanSachs

[MedCity News @medcitynews]

PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types https://t.co/Fx7SJQcCWD

[pmvpharma @pmvpharma]

@pmvpharma is pleased to announce President & CEO David H. Mack, Ph.D. will participate in a fireside chat at the @GoldmanSachs Global Healthcare Conference, taking place June 14-16.

For more information, please visit https://t.co/aWbJfUt621.

#CEO #firesidechat #GoldmanSachs

[pmvpharma @pmvpharma]

@pmvpharma is pleased to announce initial PC14586 phase 1 data presented at ASCO demonstrated anti-tumor activity across multiple solid tumor types with a p53 Y220C mutation.

Read the full press release here:

https://t.co/XQ0hcZ5RPY

#oncology #ASCO22

[pmvpharma @pmvpharma]

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting https://t.co/fmwh27THX1

[pmvpharma @pmvpharma]

@pmvpharma is pleased to announce the online publication of the abstract for our lead program, PC14586, which has been accepted as an oral presentation at @ASCO's annual meeting being held June 3-7, 2022 in Chicago, Illinois.

You can learn more here:

https://t.co/VBZkIPeUuu